MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
MD Anderson 2020 Updates on Melanoma Staging & Diagnosis: Microscopic Examination, Breslow Thickness/Depth, Clark Level, Ulceration, Mitotic Index, Lymphovascular/Perineural Invasion, TIL, SLN, Regression
FEATURING
Victor Prieto
- November 19, 2020
MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
MD Anderson 2020 Updates on Surgical Management of Melanoma: Does Complete Lymph Node Dissection Improve DMFS vs. No Dissection in SLN+ Disease? How Often Do We Use HILP/ILI vs. Systemic Therapy?
FEATURING
Jeff Gershenwald
- November 19, 2020
MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
MD Anderson 2020 Updates on Oncolytic IO for Advanced Melanoma: Is T-VEC Mono Effective in Resectable Disease? Does T-VEC + CPI Combo Work? Which Options Are Considered in Neoadjuvant and PD-1 Resistant Setting?
FEATURING
Merrick Ross
- November 19, 2020
- 1
MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
MD Anderson 2020 Update on IO for Metastatic Melanoma: What Is the 5-Year OS With Single-Agent PD-1 & PD-/CTLA-4 Agents? Which Options to Consider After Progression on PD-1(+/- Ipi)?
FEATURING
Michael Davies
- November 19, 2020
MD Anderson's The Art and Science of Managing the New Melanoma Landscape 2020
MD Anderson 2020 Updates on Advanced Melanoma: Ipi/Pembro Mono and Ipi+Nivo PFS/OS Data for CNS Metastases, Intracranial Response With Dabrafenib+Trametinib in BRAF V600-Mutated Disease
FEATURING
Isabella Glitza-Oliva
- November 19, 2020
